This is a repository copy of *Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes-A nationwide evaluation of clinical practice.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/85553/>

Version: Submitted Version

Article:

Mungreiphy, N.K., Mamza, J., Lakhdar, A.F. et al. (3 more authors) (2015) Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes-A nationwide evaluation of clinical practice. *Current Medical Research and Opinion*, 31 (3). 493 - 501. ISSN 0300-7995

<https://doi.org/10.1185/03007995.2015.1008689>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Original Article

Clinical use and efficacy of the biphasic insulin Humalog Mix50 in people with insulin treated diabetes – a nationwide evaluation of clinical practice

N.K. Mungreiphy, J. Mamza, A.F. Lakhdar, M. Bannister, J. Elliott, I. Idris

doi: 10.1185/03007995.2015.1008689

Abstract

Objectives: This study aims to investigate the metabolic effects of Humalog Mix50 in routine clinical practice. 229 patients ≥ 18 years old with diabetes, newly treated Humalog Mix50, were sourced from 6 secondary care services in the England.

Methods: Detailed clinical parameters were compared at baseline, 3 and 6 months post initiation. Responders was defined as HbA1c $< 7.5\%$ (58mmol/mol) and/or HbA1c reduction of $> 1\%$ (11mmol/mol) at 6 months.

Results: HbA1c showed significant reduction: -0.93% (-10mmol/mol) and -1.2% (-13mmol/mol) at 3 and 6 months respectively, while no significant

change was noted for all the other parameters. When analysed according to frequencies of injections/day, greatest reduction was observed with the three-times a day regimen -1.0% (-11.0mmol/mol) and -1.3% (-14.6mmol/mol) at 3 and 6 months respectively]. HbA1c reduction was greatest in the group who previously received a basal-bolus insulin regimen: $[-0.8\%$ (-9.0mmol/mol) and -1.5% (-16.2mmol/mol) at 3 and 6 months respectively]. Reduction in weight was observed at 3 months ($-1.8\text{kg} \pm 4.3$) only for those who were previously on a basal-bolus insulin regimen. Insulin doses increased following conversion to Humalog Mix50, irrespective of the types of insulin used prior Humalog Mix50, but not associated with weight gain. The independent predictors of response to Humalog Mix50, were baseline HbA1c, Caucasian, presence of nephropathy, prior use of basal-bolus insulin and prior use of other premixed combination.

Conclusion: Humalog Mix50 is therefore an effective therapeutic option for achieving glycaemic control in patients with suboptimal HbA1c levels, especially among those who were previously on basal-bolus insulin regimen and those who received it three times daily, with a neutral effect on weight parameters.

Limitations: This was a retrospective study of routine clinical practice and is therefore limited by allocation bias and some missing data. Information on rates of hypoglycaemia and quality of life are not available.

© 2014 Informa UK Ltd. This provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

DISCLAIMER: The ideas and opinions expressed in the journal's *Just Accepted* articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in these articles. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosages, the method and duration of administration, and contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. *Just Accepted* articles have undergone full scientific review but none of the additional editorial preparation, such as copyediting, typesetting, and proofreading, as have articles published in the traditional manner. There may, therefore, be errors in *Just Accepted* articles that will be corrected in the final print and final online version of the article. Any use of the *Just Accepted* articles is subject to the express understanding that the papers have not yet gone through the full quality control process prior to publication.

Clinical use and efficacy of the biphasic insulin Humalog Mix50 in people with insulin treated diabetes – a nationwide evaluation of clinical practice

N.K. Mungreiphy¹, J. Mamza¹, A.F. Lakhdar², M. Bannister³, J. Elliott⁴, I. Idris¹

¹Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, UK

²Whipps Cross University Hospital, London

³Bradford and Airedale NHS trust, Bradford

⁴Academic Unit of Diabetes, Endocrinology and Metabolism, Department of Human Metabolism, The University of Sheffield, Sheffield, UK

Address for correspondence: Iskandar Idris, Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Uttoxeter Road, DE22 3NE, UK. Tel: +44 (0) 1332 724668; Fax: +44 (0) 1332 724697; Iskandar.idris@nottingham.ac.uk

Key words: Humalog mix50; Insulin; Routine clinical practice; HbA1c

[Short title: Clinical use and efficacy of the biphasic insulin Humalog Mix50]

Abstract

Objectives: This study aims to investigate the metabolic effects of Humalog Mix50 in routine clinical practice. 229 patients ≥ 18 years old with diabetes, newly treated Humalog Mix50, were sourced from 6 secondary care services in the England.

Methods: Detailed clinical parameters were compared at baseline, 3 and 6 months post initiation. Responders was defined as HbA1c $< 7.5\%$ (58mmol/mol) and/or HbA1c reduction of $> 1\%$ (11mmol/mol) at 6 months.

Results: HbA1c showed significant reduction: -0.93% (-10mmol/mol) and -1.2% (-13mmol/mol) at 3 and 6 months respectively, while no significant change was noted for all the other parameters. When analysed according to frequencies of injections/day, greatest reduction was observed with the three-times a day regimen -1.0% (-11.0mmol/mol) and -1.3% (-14.6mmol/mol) at 3 and 6 months respectively]. HbA1c reduction was greatest in the group who previously received a basal-bolus insulin regimen: -0.8% (-9.0mmol/mol) and -1.5% (-16.2mmol/mol) at 3 and 6 months respectively]. Reduction in weight was observed at 3 months ($-1.8\text{kg} \pm 4.3$) only for those who were previously on a basal-bolus insulin regimen. Insulin doses increased following conversion to Humalog Mix50, irrespective of the types of insulin used prior

Humalog Mix50, but not associated with weight gain. The independent predictors of response to Humalog Mix50, were baseline HbA1c, Caucasian, presence of nephropathy, prior use of basal-bolus insulin and prior use of other premixed combination.

Conclusion: Humalog Mix50 is therefore an effective therapeutic option for achieving glycaemic control in patients with suboptimal HbA1c levels, especially among those who were previously on basal-bolus insulin regimen and those who received it three times daily, with a neutral effect on weight parameters.

Limitations: This was a retrospective study of routine clinical practice and is therefore limited by allocation bias and some missing data. Information on rates of hypoglycaemia and quality of life are not available.

Introduction

There is currently no consensus about the most appropriate insulin regimen to be chosen in people with diabetes [1]. NICE guidelines however recommend initiating insulin therapy with human neutral protamine Hagedorn (NPH) insulin or a long-acting analogue (basal insulin) injected at bed-time or twice daily according to the patient's need. [2] Thereafter, therapy can be intensified with prandial insulin (which may include a premixed therapy or basal-bolus regimen). While such basal-bolus insulin is widely regarded as the 'gold standard' insulin regimen in people with diabetes, the technicalities of this regimen coupled with the need for frequent insulin

dose adjustment resulted in our observation that in routine practice, glycaemic control remains suboptimal in many patients receiving a basal bolus insulin regimen. [3]

In people without diabetes, basal insulin secretion represents approximately 50% of insulin secretion, with the remaining 50% being meal related insulin secretion [4]. Among patients with type 2 diabetes requiring intensive insulin therapy regimens in the form of multiple daily injection or insulin pump therapy, both regimen required 50% basal and 50% rapid acting insulin following dose titration [5]. Based on these, biphasic insulin lispro 50/50 (Humalog Mix50) containing 50% rapid-acting and basal insulin respectively, was developed to provide the physiological advantages of rapid and basal insulin in the convenience of a premixed formulation [6]. Indeed, intensification of insulin therapy (where patients' blood glucose levels remain suboptimal after receiving biphasic insulin aspart 30/70, biphasic human insulin 30/70 or biphasic insulin lispro 25/75) has been shown to be achieved by switching to premixed regimens with greater prandial coverage (Humalog Mix50) [7,8,9]. There is however, limited post-market surveillance and/or real world evidence assessing how Humalog Mix50 is used in routine practice, as well as the effectiveness of this insulin regimen in patients with diabetes. This study specifically aims to investigate how this insulin is used in routine practice in the UK (e.g. first line, second line, third line insulin twice daily, thrice daily or in combination with prandial or basal insulin) as well as the effectiveness of Humalog Mix50 regimen in patients with diabetes.

Methods

Patient Selection and Analyses

Anonymised retrospective information on 229 patients using Humalog Mix50 in clinical practice was received from 6 centres across England. Demographic data of the patients which includes ethnicity, gender, type of diabetes, year of diabetes diagnosis, hypoglycaemia unawareness, height, weight and medications were included in the audit. At baseline, patients were divided according to the type of diabetes for analyses. Information on complications like stroke, peripheral artery disease, retinopathy, nephropathy and neuropathy were also assessed. Data were collated at the third and sixth month post commencement of Humalog Mix50. All patients who had received Humalog Mix50 with available data for at least 6 months were eligible for inclusion.

Data on the current antidiabetic and insulin therapy with details of dosing frequency and year of start were noted. Information on antidiabetic therapy including insulin prior to Humalog Mix50 therapy and after starting Humalog Mix50 therapy at 3 and 6 months were evaluated.

Comparison of the changes in the patients' HbA1c, weight, BMI, eGFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP prior to starting Humalog Mix50 therapy and Humalog Mix50 at 3 and 6 months post Humalog Mix50 initiation were calculated.

Statistical Analysis

Descriptive statistics are provided for patients according to their type of diabetes. Changes in HbA1c, weight, BMI, eGFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP

from prior to starting Humalog Mix50 therapy and after starting Humalog Mix50 therapy at 3 and 6 months were evaluated using paired t-test. Analysis of variance (ANOVA) was used to check the variation in Mean ($\pm$ SD) of different variables. p-values of <0.05 were considered to be statistically significant in the analyses.

ANOVA was applied to assess the effect of different dosing frequency of Humalog Mix50 therapy per day on the patients' HbA1c, weight, BMI, eGFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP at the third and sixth months. Changes after starting Humalog Mix50 therapy at 3 and 6 months were also evaluated according to the patients' prior medication using ANOVA. Statistical analyses were performed using StataSE 11

Results

There were two hundred and twenty-nine patients with detailed baseline information. Demographic information of patients is shown in table 1. Most of the patients were Caucasian. Thirty two patients have type 1 diabetes while one hundred and ninety seven patients have type 2 diabetes, with mean type 2 diabetes duration of $18.35 (\pm 7.9)$ years. Negligible amount of patients experienced hypoglycaemia unawareness. Mean HbA1c at baseline was 85mmol/mol (9.9%) and mean BMI was 34.8kg/m^2 (Table 1). Micro- and macro vascular complications were significantly more prevalent in patients with type 2 diabetes. The majority of patients (51.7%) received a premixed insulin therapy as their first insulin regimen. Prior to Humalog Mix50 therapy, most patients were on premixed insulin 30/70 (46.3%) and/or Metformin (47.2%) while few received Basal Bolus insulin (6.1%), Basal Acting (11.97%) or other oral therapy (14.4%)

such as Gliptins, Glucagon like peptide-1 analogues, sulphonylureas and thiazolidinediones. Most patients (40.4%) took Humalog Mix50 as their current insulin therapy three times daily with mean doses of 135.1 ± 75.3 units per day (1.4 ± 0.7 U/kg), followed by those (24.1% each) who took four times daily with mean doses of 90.6 ± 62.7 units per day (0.93 ± 0.7 U/kg) and twice daily with mean doses of 90.6 ± 62.7 units per day (0.78 ± 0.4 U/kg). There were only 11.4% patients who had Humalog Mix50 once a day with mean dose of 46.1 ± 68.7 units per day (0.49 ± 0.3 U/kg).

Table 2 shows the mean values of weight, BMI, HbA1c, GFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP, prior to starting Humalog Mix50 therapy and at 3 and 6 months after starting Humalog Mix50. HbA1c showed significant reduction at both time points of investigation while no significant change was noted for all the other parameters following the initiation of Humalog Mix50 (Table 2). However, when changes in parameters at 3 and at 6 months were analysed according to frequencies of Humalog Mix50 injections per day, we observed significant differences for most parameters depending on the frequencies of Humalog Mix50 therapy being used (Table 3). HbA1c reduction was seen for all frequencies of Humalog Mix50 injection therapy (Figure 1), with the greatest reduction observed with the three times a day regimen. Patients who took Humalog Mix50 four times a day showed reduction of weight and BMI at both 3 and 6 months, whereas patients with three and two times injections/day showed increment in the values. Total cholesterol and triglyceride levels were unchanged following initiation of Humalog Mix50.

The changes in weight, BMI, HbA1c, GFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP after starting Humalog Mix50 therapy according to prior medication is reported in table 4. Among patients who were on basal bolus prior to Humalog Mix50 therapy, reduction in weight was observed at 3 months whereas the values increased at 3 and 6 months among those who were previously taking premix and basal insulin medication. HbA1c outcomes following Humalog Mix50 were significantly different depending on the insulin regimen used prior to Humalog Mix50. At 6 months, HbA1c reduction appears to be greatest in the group who previously received a basal bolus insulin regimen (Figure 2). Of note, in a separate subanalysis, similar outcome was observed among patients with type 2 diabetes as that from the whole cohort (result not presented here). Insulin doses increased following conversion to Humalog Mix50, irrespective of the types of insulin used prior to conversion to Humalog Mix50 (Table 5). The patient group who received the greatest amount of insulin were those who previously received a basal bolus insulin group prior to conversion to Humalog Mix50, (increase in insulin dose from 0.78u/kg to 1.2u/kg. Reassuringly, this was not associated with weight gain (Table 4).

Table 6 displays the logistic regression showing predictors of responders (n=170) versus non-responders (n=59) to Humalog Mix50 therapy. Responder was defined as HbA1c reduction by 1% or more at 3 months or 6 months or achieving HbA1c <7.5%% (58mmol/mol) at 6 months if baseline HbA1c >=7.5%(58mmol/mol). The response rate was 74%. The independent predictors of response to Humalog Mix50, after adjusting for other confounders were baseline HbA1c, Caucasian, presence of nephropathy and prior use of basal bolus insulin as well as prior use of other premixed combination (other than Humalog Mix50).

Discussion

This audit of Humalog Mix50 provides useful insights into the current strategies in Humalog Mix50 prescribing as well as clinical effectiveness of this insulin in routine specialist clinical care in England. The audit also allowed some analyses of the predictors of good glycaemic responses to Humalog Mix50, comparisons between different frequencies of Humalog Mix50 being prescribed, as well as analyses of effectiveness and weight outcome, based on previous insulin regimen used prior to Humalog Mix50.

As a whole, this audit suggests that biphasic insulin regimen mix30 appears to be the most widely used first line insulin regimen in clinical practice. When prescribed, Humalog Mix50 is often prescribed as a third or 4th line insulin regimen and is associated with a reduction in HbA1c at 3 and at 6 months. The rate of responders to Humalog Mix50 - based on our strict definition of responders, (reduction in HbA1c by >1% or achieving HbA1c target of <7.5%(58mmol/mol), observed in this study was very high (74%), compared with only 35% of patients who responded to this insulin regimen seen in our previous study [10]. This may reflect the fact that the data from this audit was derived from data from specialist centres, whereas our previous data was derived from a UK general practice dataset.

The majority of Humalog Mix50 is prescribed three times a day, which was also associated with the highest insulin dose/kg of insulin, compared with other frequencies of Humalog Mix50 injection. This frequency of insulin injection is associated with weight gain. Although insulin intensification is widely recognised to be associated with weight gain [11,12], previous data has shown favourable effects of Humalog Mix50 regimen on weight [10,13]. No difference in

HbA1c reduction was observed across different frequencies of Humalog Mix50 injections, although greatest HbA1c reduction was observed among those who were prescribed three times day. In line with this, previous studies have shown benefits of Humalog Mix50 compared to human insulin 70/30 or Humalog 75/25 [9,13] in reducing post-prandial glucose excursion [6]. These benefits were augmented when Humalog Mix50 is given thrice daily compared with 70/30 twice daily [9] or 70/30 thrice daily [14], but equivalent when compared with a basal bolus insulin regimen [15].

When analysed according to the previous insulin regimen being used, those who converted to Humalog Mix50 from a previous basal bolus insulin regimen appears to show the greatest reduction in HbA1c, compared with those who was previously on a biphasic 30 or a long acting only insulin. The reason for this is unclear, and is out of the scope of this audit. It is tempting to speculate that the complexities of a basal bolus insulin regimen when prescribed in obese patients with diabetes (such as in this patient cohort), is associated with reduced treatment compliance and hence treatment failure. To this end, converting these patients to a more fixed biphasic insulin regimen, with an appropriate prandial insulin cover might be beneficial. Indeed, previous use of basal bolus insulin (along with the recognised, baseline HbA1c) is an independent predictor of success to Humalog Mix50 regimen. Presence of diabetic nephropathy, perhaps by virtue of declining GFR and increased risks of hypoglycaemia is also a predictor of response to Humalog Mix50. Of note however, the patient group who received the greatest amount of insulin were those who previously received a basal bolus insulin group prior to conversion to Humalog Mix50, (increase in insulin dose from 0.78u/kg to 1.2u/kg), but this was not associated with weight gain. The explanation in the discordance between weight loss (at 3months) and increased insulin dose unfortunately is outside the remit of this study, but we

would speculate that changes in lifestyle, compliance to treatment and eating habits from converting from a 4 injections a day to a fixed three injections per day may somewhat play a role in this.

The magnitude of HbA1c reduction in this cohort was similar to that previously observed in the national exenatide audit in patients not on insulin [17]. However, in the same audit, HbA1c reduction was much less at three months among those who were on insulin and continued on insulin therapy (-0.51%) or among patients who discontinued insulin therapy following initiation of exenatide [17]. Patients in the previous exenatide audit however consisted entirely of patients with type 2 diabetes and were therefore slightly heavier (BMI 40.3, 40.2 and 39.4 respectively for different groups) than patients in this present audit (mean BMI 34.8kg/m²).

This analysis had several limitations. Firstly, there was incomplete HbA1c and weight data due to problems of an audit in real-life clinical practice (e.g. missed follow-up, missed measurements or incomplete data entry). This has the potential of introducing bias among available results. Secondly, variability in clinical practice would influence insulin intensification strategy between centres. It important to note however that all data were collected from specialist centres with patients receiving input by specialist clinicians. We were also unable to determine treatment compliance and variations in structured education programmes that patients may or may have not received. We also did not distinguish between type 1 and type 2 diabetes in our analysis because the small number of patients with type 1 diabetes in this data would limit any meaningful conclusion to patients with type 1 diabetes. However, where appropriate, we performed subanalysis in patients with type 2 diabetes alone, and the result was similar to the whole cohort. In addition, other than metabolic outcome, the aim of this study is look at prescribing pattern of Humalog Mix50 among all insulin treated patients with diabetes. Finally, data on quality of life

and hypoglycaemia is not available in this study. This is crucial, since any possible improvement in HbA1c, maybe driven by reduction in the frequency of insulin treatment, hypoglycaemia risks or lack of need to adjust insulin doses according to carbohydrate load.

Conclusion

Conversion to Humalog Mix50 regimen appears to be a reasonable therapeutic option among patients who are already on insulin therapy, with suboptimal glucose control. Although the glycaemic response of this insulin regimen is heterogeneous; patients who were previously on a basal bolus insulin regimen and those who received three times a day Humalog Mix50 appeared to benefit most with a neutral effect on weight parameters.

Transparency

Declaration of funding:

This study was funded by an un-restricted grant from Eli Lilly Pharmaceutical. Eli Lilly provided no further input in data acquisition, data access, analysis and interpretation of the data.

Declaration of financial/other relationships:

II has received research grants and speakers fees from Eli Lilly and Novo Nordisk. JE and AL have received speaker fees from Eli Lilly, MSD, Novo Nordisk, Sanofi, and have also received advisory board fees from Sanofi. MB has received speaker fees from Eli Lilly, Boehringer Ingelheim, and advisory board fees from Novo Nordisk. CMRO Peer Reviewer 1 has no relevant financial or other relationships to disclose. CMRO Peer Reviewer 2 has received grants from the Russian Scientific Foundation; is a consultant to and the National coordinator of RTCs for AstraZeneca and AbbVie; and is on the Speakers' Bureau of Eli Lilly, Novartis, Novo Nordisk, MSD and AstraZeneca.

References

- 1 Nathan, D.M., et al., Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*, 2006. **49**(8): p. 1711-21.
- 2 National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. 2009 [cited 2013 19th July]; Available from: <http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf>.
- 3 Owen V, Seetho I, Idris I. Predictors of responders to insulin therapy in type 2 diabetes among adults with type 2 diabetes. *Diabetes, Obesity and Metabolism*, 2010. **12** (10):865-70
- 4 Polonsky KS, Given BD, Van Cauter E. Twenty-four hour profiles and pulsatile patterns of

insulin secretion in normal and obese subjects. J Clin Invest. 1988. **81**(2):442-8

5 Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P. A clinical trial of continuous subcutaneous infusion versus multiple daily injection in older adults with type 2 diabetes. Diabetes Care. 2005. **28**(7):1568-73

6 Schwartz, S., et al., A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clinical therapeutics, 2006. **28**(10): p. 1649-1657.

7 Tanaka, M. and H. Ishii, Pre-Mixed Rapid-Acting Insulin 50/50 Analogue Twice Daily is Useful Not Only for Controlling Post-Prandial Blood Glucose, but Also for Stabilizing the Diurnal Variation of Blood Glucose Levels: Switching from Pre-Mixed Insulin 70/30 or 75/25 to Pre-Mixed Insulin 50/50. Journal of International Medical Research, 2010. **38**(2): p. 674-680.

8 Shimizu, H., et al., Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients. Yonsei Med J, 2010. **51**(6): p. 845-9.

9 Scherthaner, G., et al., Metabolic Control in Patients with Type 2 Diabetes Using Humalog® Mix50™ Injected Three Times Daily: Crossover Comparison with Human Insulin 30/70. Horm Metab Res, 2004. **36**(03): p. 188-193.

10 Mamza J, Mehta R, Idris I. BMJ Open Diabetes Research and Care 2014;2:e000021.

doi:10.1136/bmjdr-2014-000021

11 Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; **280**: 140–146.

12 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; **352**: 837–853.

13 Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lisipro or insulin lisipro mid mixture vs basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. Journal of Diabetes and its complications. 2006. **20**: 145-52

14 Masuda H, Sakamoto M, Irie J, Kitaoka A, Shiono K, Inoue G, Atsuda K, Yamada S. Comparison of twice daily injections of biphasic insulin lisipro and basal bolus therapy: glycaemic control and quality of life of insulin-naïve type 2 diabetic patients. Diabetes, Obesity & Metabolism. 2008. **10**(12):1261-5

15 Nichols GA, Hillier TA, Javor K, Brown JB. Predictors of glycaemic control in Insulin-using adults with type 2 diabetes. Diabetes Care 2000; **23**:272–277.

16 Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. *Int J Clin Pract.* 2008; 62:1647-53. doi: 10.1111/j.1742-1241.2008.01909.x.

17 Thong KY, Jose B, Blann AD, Cull ML, Mills AP, Sathyapalan T, Walton C, Ryder RE. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. *Diabetes Res Clin Pract.* 2011; 93:e87-91. doi: 10.1016/j.diabres.2011.05.015.

JUST ACCEPTED

Table 1: Demographic and baseline characteristics of the patients

Variables (%)	Total (n=229) / Mean (SD)	Type 1 Diabetes (n=32)	Type 2 Diabetes (n=197)	p-Value
Ethnicity				
Caucasian	166 (72.4)	29 (17.5)	137 (82.5)	0.013
Non-Caucasian	63 (27.6)	3 (4.76)	60 (95.2)	
Gender				
Males	117 (51.1)	19 (16.24)	98 (83.8)	0.312
Females	112 (48.9)	13 (11.6)	99 (88.4)	
Hypoglycaemia unawareness				
Yes	25 (11.7)	10 (40)	15 (60)	<0.001
No	188 (88.3)	20 (10.6)	168 (89.3)	
Complications				
Stroke	20 (8.7)	0	20 (100)	0.034
Peripheral Artery	35 (15.3)	0	35 (100)	0.004
Retinopathy	138 (60.3)	17 (12.3)	121 (87.7)	0.029
Nephropathy	102 (44.5)	7 (6.9)	95 (93.1)	<0.001
Neuropathy	104 (45.4)	5 (4.8)	99 (95.2)	<0.001
First insulin regimen				

Variables (%)	Total (n=229) / Mean (SD)	Type 1 Diabetes (n=32)	Type 2 Diabetes (n=197)	p-Value
HumalogMix50	27 (18.1)	2 (7.4)	25 (92.6)	0.735
Basal Insulin	36 (24.2)	6 (16.7)	30 (83.3)	
Premixed	80 (53.7)	10 (12.5)	70 (87.5)	
Short acting	6 (4.0)	1 (16.7)	5 (83.3)	
Mean Age (years)	63.18 (12.6)	52.84 (18.2)	64.86 (10.5)	<0.001
Diabetes duration (years)	19.12 (9.4)	24.1 (15.2)	18.35 (7.9)	<0.001
Duration of insulin regimen (years)	11.41 (9.2)	21.71 (15.9)	9.64 (6)	<0.001
Height (m)	1.66 (0.1)	1.68 (0.1)	1.66 (0.1)	0.805
Weight (kg)	96.76 (23.9)	81.02 (17.6)	99.15 (23.9)	0.049
BMI (kg/m²)	34.8 (7.8)	28.48 (5.8)	35.81 (7.6)	0.086
HbA1c (%)	9.9 (2.1)	9.64 (2.2)	9.95 (2.0)	0.568
HbA1c (mmols/mol)	85 (23)	82 (24)	85 (21.9)	0.568
eGFR (mls/min/m²)	69.76 (63)	78.46 (23.4)	68.35 (67.2)	<0.001
Total cholesterol (mmol/L)	4.31 (1.1)	4.51 (1.1)	4.28 (1.1)	0.922
Triglyceride (mmol/L)	2.50 (1.6)	1.76 (1.8)	2.63 (1.5)	0.217
HDL (mmol/L)	1.19 (0.4)	1.57 (0.46)	1.12 (0.4)	0.091
LDL (mmol/L)	2.05 (0.8)	2.12 (0.8)	2.03 (0.9)	0.617
Systolic BP (mmHg)	138.24 (18.8)	128.07 (11.7)	139.84 (19.2)	0.002
Diastolic BP (mmHg)	73.88 (11.1)	72.47 (8.03)	74.10 (11.5)	0.02

Values are quoted as count/actual numbers (%) or as mean ($\pm$ sd.)

Table 2: Mean of the variables prior to starting Humalog Mix50 therapy and at 3rd and 6th months after starting Humalog Mix50 along with the differences of the means and level of significance

Variables	Prior to starting Humalog Mix 50 therapy		3 months after starting Humalog Mix50		Differences in 3 months		6 months after starting Humalog Mix50 therapy		Differences in 6 months	
	n	Mean (sd)	n	Mean (sd)	Mean change (3 rd month-prior)	p-value	n	Mean (sd)	Mean change (6 th month-prior)	p-value
Weight (kg)	220	96.8 (23.9)	139	94.8 (23.8)	-1.04 (4.6)	0.451	194	97.9 (25.9)	1.0 (9.6)	0.657
BMI (kg/m²)	213	34.8 (7.8)	135	34.6 (8.7)	-0.42 (1.8)	0.850	187	35.4 (8.8)	0.41 (3.4)	0.441
HbA1c (%)	227	9.9 (2.1)	159	9.2 (1.7)	-0.93 (1.6)	0.001	210	8.7 (1.7)	-1.18 (1.9)	P<0.001
HbA1c (mmols/mol)	227	85 (23.0)	159	77 (18.6)	-10.2 (17.5)	0.001	210	73 (18.6)	-12.9 (20.8)	P<0.001
eGFR (mls/min/m²)	214	69.8 (63)	133	66.3 (25.2)	-9.4 (11.2)	0.544	181	67.7 (67.8)	-2.28 (89.1)	0.750
Total cholesterol (mmol/L)	210	4.3 (1.1)	111	4.3 (1.3)	-0.01 (.8)	0.715	168	4.3 (1.0)	-0.05 (.9)	0.858
Triglyceride	188	2.5 (1.6)	100	2.6 (1.7)	-0.13 (1.2)	0.845	149	2.3 (1.5)	-0.30 (1.2)	0.265

(mmol/L)										
HDL (mmol/L)	169	1.2 (0.4)	85	1.2 (0.4)	0.01 (0.3)	0.853	141	1.2 (.4)	-0.02 (.3)	0.820
LDL (mmol/L)	127	2.1 (0.8)	66	2.1 (0.7)	-0.01 (.7)	1.000	108	2.0 (.7)	-0.06 (.8)	0.774
Systolic BP (mm/Hg)	221	138.2 (18.8)	132	135.1 (16.7)	-0.29 (17.0)	0.109	183	137.4 (17.9)	-0.13 (20.4)	0.633
Diastolic BP (mm/Hg)	221	73.8 (11.1)	132	74.60 (9.9)	0.65 (11.6)	0.540	183	73.1 (11.1)	-1.04 (11.5)	0.488

Table 3: Changes after starting Humalog Mix50 therapy at 3rd and 6th months according to frequency per day

Variables	Mix50 Freq per day	Mean change in variables at 3 months (3 months & prior)			Mean change in variables at 6 months (6 months & prior)		
		Mean (SD)	Freq	p-value	Mean (SD)	Freq	p-value
Weight (kg)	Four Times	-.83 (2.5)	13		-1.92 (18.2)	37	
	Three Times	.91 (4.9)	72		2.26 (6.6)	84	
	Two times	1.73 (3.5)	40		1.50 (4.1)	48	
	Once	1.51 (7.2)	13		-.06 (4.8)	21	
	Total	1.04 (4.6)	138	<0.001	1.00 (9.6)	190	<0.001
BMI (kg/m ²)	Four Times	-.29 (.9)	13		-.66 (6.3)	36	
	Three Times	.38 (1.9)	72		.89 (2.5)	83	
	Two times	.69 (1.2)	37		.56 (1.5)	45	
	Once	.61 (2.9)	12		-.01 (1.8)	20	
	Total	.42 (1.8)	134	<0.001	.41 (3.4)	184	<0.001
HbA1c (%)	Four Times	-.90 (1.6)	21		-.92 (2.4)	42	
	Three Times	-1.01 (1.5)	78		-1.34 (1.7)	90	
	Two times	-0.89 (1.8)	46		-1.13 (2.0)	51	
	Once	-0.52 (0.9)	11		-1.20 (2.0)	24	

	Total	-0.92 (1.8)	156	0.089	-1.18 (1.9)	207	0.069
GFR (mls/min/m ²)	Four Times	-6.51 (21.2)	15		-3.23 (199.8)	35	
	Three Times	1.17 (9.0)	66		-2.27 (16.5)	78	
	Two times	-1.63 (6.4)	38		-2.5 (9.4)	42	
	Once	-4.55 (15.3)	10		-.19 (17.8)	20	
	Total	-.99 (11.2)	129	<0.001	-2.28 (89.3)	175	<0.001
Total cholest- terol (mmol/L)	Four Times	.11 (.5)	17		-.09 (1.0)	35	
	Three Times	-.04 (.9)	55		-.07 (.9)	71	
	Two times	-.05 (.8)	29		-.05 (.8)	35	
	Once	.20 (.3)	5		.13 (1.1)	19	
	Total	-.01 (.8)	106	0.011	-.05 (.9)	160	0.344
Trigly-ceride (mmol/L)	Four Times	-.54 (.8)	11		-.32 (1)	25	
	Three Times	-.07 (1.2)	50		-.30 (1.4)	62	
	Two times	.02 (1.3)	26		-.29 (1.1)	29	
	Once	-.42 (.6)	5		-.25 (1.1)	17	
	Total	-.12 (1.2)	92	0.157	-.30 (1.2)	133	0.092
HDL (mmol/L)	Four Times	-.03 (.6)	16		-.09 (.5)	34	
	Three Times	.01 (.2)	35		-.03 (.2)	43	
	Two times	.04 (.2)	20		.03 (.2)	26	
	Once	0 (.1)	4		.04 (.2)	18	
	Total	.01 (.3)	75	<0.001	-.02 (.3)	121	<0.001
LDL (mmol/L)	Four Times	.28 (.5)	15		-.01 (.8)	31	
	Three Times	-.08 (.9)	26		-.21 (.7)	28	
	Two times	-.33 (.7)	13		-.13 (.8)	15	
	Once	.25 (.1)	4		.18 (1)	16	
	Total	-.02 (.8)	58	0.007	-.06 (.8)	90	0.440
Systolic BP (mm/Hg)	Four Times	-3.94 (24.18)	16		-3.08 (22.69)	37	
	Three Times	-.33 (15.88)	69		.12 (20.27)	78	
	Two times	4.77 (15.17)	35		3.37 (20.07)	43	
	Once	-3.91 (16.74)	11		-.85 (16.90)	20	
	Total	.29 (17.04)	131	0.108	.129 (20.36)	178	0.558
Diastolic BP (mm/Hg)	Four Times	3.44 (16.05)	16		-4.11 (11.46)	37	
	Three Times	-.93 (10.19)	69		-.76 (10.40)	78	
	Two times	1.91 (10.80)	35		.09 (13.56)	43	
	Once	2.45 (14.83)	11		1.05 (10.11)	20	
	Total	.65 (11.60)	131	0.054	-1.04 (11.45)	178	0.211

Table 4: Changes after starting Humalog Mix50 therapy at 3rd and 6th months according to insulin medication prior to conversion to Mix50

Changes in Variable	Prior Medication	Mean change at 3 months (3 months-prior)			Mean change at 6 months (6 months-prior)		
		Mean SD	Freq	p-value	Mean SD	Freq	p-value
Weight (kg)	Premix	1.31 (4.1)	60		.09 (12)	83	
	Basal Bolus	-1.79 (4.3)	8		.09 (2.2)	10	
	Basal Ins	1.46 (6)	19		1.15 (7.5)	26	
	Total	1.06 (4.6)	87	0.110	.32 (10.6)	119	<0.001
BMI (kg/m ²)	Premix	0.49 (1.5)	58		.04 (4.0)	80	
	Basal Bolus	-0.70 (1.7)	8		.01 (.8)	10	
	Basal Ins	0.54 (2.2)	18		.40 (2.5)	25	
	Total	.39 (1.7)	84	0.261	.11 (3.5)	115	<0.001
HbA1c (%)	Premix	-.64 (6.9)	69		-.85 (1.7)	93	
	Basal Bolus	-.82 (0.7)	9		-1.48 (1.3)	11	
	Basal Ins	-.43 (1.8)	24		-.87 (2.6)	30	
	Total	-.06 (5.7)	102	0.016	-.91 (1.9)	134	0.005
GFR (mls/min/m ²)	Premix	-0.40 (12.9)	61		-11.41 (94.3)	80	
	Basal Bolus	-7.54 (16.4)	8		2.21 (9.5)	10	
	Basal Ins	-2.81 (7.9)	20		-3.07 (10.6)	25	
	Total	-1.59 (12.3)	89	0.028	-8.42 (78.8)	115	<0.001

Total	Premix	.18 (0.7)	46		-.01 (.8)	74	
cholesterol	Basal Bolus	.37 (0.4)	3		-.16 (.6)	8	
(mmol/L)	Basal Ins	.19 (0.7)	20		.27 (.6)	23	
	Total	.19 (0.7)	69	0.632	.04 (.8)	105	0.088
Triglycerid	Premix	-.22 (1)	37		-.20 (1.3)	61	
e (mmol/L)	Basal Bolus	-1.17 (1.1)	3		-.64 (1.9)	7	
	Basal Ins	.55 (1.3)	17		.02 (.7)	19	
	Total	-.04 (1.2)	57	0.424	-.19 (1.2)	87	0.041
HDL	Premix	-.02 (.4)	31		-.06 (.4)	52	
(mmol/L)	Basal Bolus	.033 (.1)	3		.04 (.1)	5	
	Basal Ins	.07 (0.2)	11		.05 (.1)	18	
	Total	.002 (0.4)	45	0.003	-.03 (.3)	75	<0.001
LDL	Premix	.13 (.4)	23		-.14 (.7)	36	
(mmol/L)	Basal Bolus	.37 (.6)	3		-.12 (.7)	5	
	Basal Ins	.55 (.4)	4		.19 (.6)	10	
	Total	.21 (.4)	30	0.822	-.08 (.7)	51	0.827
Systolic BP	Premix	.93 (16.4)	59		1.71 (18.6)	78	
(mm/Hg)	Basal Bolus	-12.13 (18.6)	8		-9.1 (16)	10	
	Basal Ins	-3.29 (22.9)	17		.5 (21.3)	26	
	Total	-1.17 (18.3)	84	0.229	.48 (19.1)	114	0.541
Diastolic	Premix	2.68 (11.2)	59		.23 (9.8)	78	
BP	Basal Bolus	-6.5 (16.6)	8		-8.8 (13.1)	10	
(mm/Hg)	Basal Ins	-5.06 (13.3)	17		-1.23 (13.3)	26	
	Total	0.24 (12.6)	84	0.273	-.89 (11.2)	114	0.107

Table 5: Total mean (sd) dose of insulin prior to Mix50 treatment = 84.7 (50.1) units/day or 0.88 (0.5)

U/kg per day. OD= once daily, BD=twice daily, TDS=three times a day, QDS= four times a day

	Prior Insulin dose (Units/Kg/Day)		Baseline Mix50 dose (Units/Kg/Day)		MD (Se)	P value
	N (%)	Mean (SD)	N (%)	Mean (SD)		
Total	141	0.88 (0.5)	215	1.03 (0.7)	0.15 (0.07)	0.01
Prior Regimen						
Basal bolus	14	0.54 (0.3)	14	0.80 (0.4)	0.26 (0.1)	0.03
Basal insulin	30	0.78 (0.5)	31	1.20 (1.0)	0.42 (0.2)	0.02
Other premixed	97	0.96 (0.5)	96	1.09 (0.6)	0.13 (0.08)	0.05
Frequency of Mix50						
OD	24	0.41 (0.3)	24	0.49 (0.3)	0.08 (0.09)	0.2
BD	95	0.98 (0.4)	51	0.77 (0.4)	-0.21 (0.07)	0.9
TDS	22	0.91 (0.5)	88	1.38 (0.7)	0.47 (0.2)	0.002
QDS	-	-	52	0.93 (0.7)		

JUST ACCEPTED

—
—
—
—

Table 6:

Predictors	OR 95% CI	p value
HbA1c (%)*	1.45 [1.21,1.74]	<0.001
Ethnicity		
Non-caucasian	1.00	-

Caucasian	1.87 [0.99,3.53]	0.05
Nephropathy		
No	1.00	
Yes	2.13 [1.06,4.27]	0.03
Prior Insulin therapy		
Basal bolus	3.67 [1.02,13.14]	0.05
Basal insulin	1.46 [0.72,2.96]	0.3
Premixed (Non-HM50)	2.89 [1.86,4.48]	0.001

Table: Logistic regression showing predictors of responders (n=170) versus non-responders (n=59) to Humalog Mix50 therapy

*Responders: Predictor of response if HbA1c reduction by 1% or more at 3 months or 6 months or achieving HbA1c < 7% at 6 months if baseline HbA1c $\geq 7.5\%$

Figure 1:

Figure 2